These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 31925985)

  • 1. ARL4C is associated with initiation and progression of lung adenocarcinoma and represents a therapeutic target.
    Kimura K; Matsumoto S; Harada T; Morii E; Nagatomo I; Shintani Y; Kikuchi A
    Cancer Sci; 2020 Mar; 111(3):951-961. PubMed ID: 31925985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arl4c expression in colorectal and lung cancers promotes tumorigenesis and may represent a novel therapeutic target.
    Fujii S; Matsumoto S; Nojima S; Morii E; Kikuchi A
    Oncogene; 2015 Sep; 34(37):4834-44. PubMed ID: 25486429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemically Modified Antisense Oligonucleotide Against ARL4C Inhibits Primary and Metastatic Liver Tumor Growth.
    Harada T; Matsumoto S; Hirota S; Kimura H; Fujii S; Kasahara Y; Gon H; Yoshida T; Itoh T; Haraguchi N; Mizushima T; Noda T; Eguchi H; Nojima S; Morii E; Fukumoto T; Obika S; Kikuchi A
    Mol Cancer Ther; 2019 Mar; 18(3):602-612. PubMed ID: 30647122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic upregulation of ARL4C, due to DNA hypomethylation in the 3'-untranslated region, promotes tumorigenesis of lung squamous cell carcinoma.
    Fujii S; Shinjo K; Matsumoto S; Harada T; Nojima S; Sato S; Usami Y; Toyosawa S; Morii E; Kondo Y; Kikuchi A
    Oncotarget; 2016 Dec; 7(49):81571-81587. PubMed ID: 27835592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted next-generation sequencing for analyzing the genetic alterations in atypical adenomatous hyperplasia and adenocarcinoma in situ.
    Xu X; Li N; Zhao R; Zhu L; Shao J; Zhang J
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2447-2453. PubMed ID: 28821955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma.
    Hu X; Fujimoto J; Ying L; Fukuoka J; Ashizawa K; Sun W; Reuben A; Chow CW; McGranahan N; Chen R; Hu J; Godoy MC; Tabata K; Kuroda K; Shi L; Li J; Behrens C; Parra ER; Little LD; Gumbs C; Mao X; Song X; Tippen S; Thornton RL; Kadara H; Scheet P; Roarty E; Ostrin EJ; Wang X; Carter BW; Antonoff MB; Zhang J; Vaporciyan AA; Pass H; Swisher SG; Heymach JV; Lee JJ; Wistuba II; Hong WK; Futreal PA; Su D; Zhang J
    Nat Commun; 2019 Jul; 10(1):2978. PubMed ID: 31278276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas.
    Sakamoto H; Shimizu J; Horio Y; Ueda R; Takahashi T; Mitsudomi T; Yatabe Y
    J Pathol; 2007 Jul; 212(3):287-94. PubMed ID: 17534846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARL4C is associated with epithelial-to-mesenchymal transition in colorectal cancer.
    Kanai R; Uehara T; Yoshizawa T; Kamakura M; Nakajima T; Kinugawa Y; Iwaya M; Asaka S; Kitazawa M; Nagaya T; Ota H
    BMC Cancer; 2023 May; 23(1):478. PubMed ID: 37237373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA.
    Izumchenko E; Chang X; Brait M; Fertig E; Kagohara LT; Bedi A; Marchionni L; Agrawal N; Ravi R; Jones S; Hoque MO; Westra WH; Sidransky D
    Nat Commun; 2015 Sep; 6():8258. PubMed ID: 26374070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma.
    Sivakumar S; Lucas FAS; McDowell TL; Lang W; Xu L; Fujimoto J; Zhang J; Futreal PA; Fukuoka J; Yatabe Y; Dubinett SM; Spira AE; Fowler J; Hawk ET; Wistuba II; Scheet P; Kadara H
    Cancer Res; 2017 Nov; 77(22):6119-6130. PubMed ID: 28951454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreasing Arl4c expression by inhibition of AKT signal in human lung adenocarcinoma cells.
    Sun Y; Zhang Z; Xiang F; Zhang M; Chen Q; Tang L; Zhu L; Liu J; Meng Z; Hu J; Luo X; Ni Z; Wang X
    Life Sci; 2020 Apr; 246():117428. PubMed ID: 32057901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung.
    Awaya H; Takeshima Y; Furonaka O; Kohno N; Inai K
    J Clin Pathol; 2005 Oct; 58(10):1076-80. PubMed ID: 16189154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical relevance of ARF/ARL family genes and oncogenic function of ARL4C in endometrial cancer.
    Zhang J; Zhang Q; Sun C; Huang Y; Zhang J; Wang Q
    Biomed Pharmacother; 2020 May; 125():110000. PubMed ID: 32070877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma.
    Selamat SA; Galler JS; Joshi AD; Fyfe MN; Campan M; Siegmund KD; Kerr KM; Laird-Offringa IA
    PLoS One; 2011; 6(6):e21443. PubMed ID: 21731750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological Characteristics and Mutations Driving Development of Early Lung Adenocarcinoma: Tumor Initiation and Progression.
    Inamura K
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29690599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis.
    Sartori G; Cavazza A; Bertolini F; Longo L; Marchioni A; Costantini M; Barbieri F; Migaldi M; Rossi G
    Am J Clin Pathol; 2008 Feb; 129(2):202-10. PubMed ID: 18208799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNA H19 is responsible for the progression of lung adenocarcinoma by mediating methylation-dependent repression of CDH1 promoter.
    Gao LM; Xu SF; Zheng Y; Wang P; Zhang L; Shi SS; Wu T; Li Y; Zhao J; Tian Q; Yin XB; Zheng L
    J Cell Mol Med; 2019 Sep; 23(9):6411-6428. PubMed ID: 31317666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor mutation and p53 overexpression during the multistage progression of small adenocarcinoma of the lung.
    Yoo SB; Chung JH; Lee HJ; Lee CT; Jheon S; Sung SW
    J Thorac Oncol; 2010 Jul; 5(7):964-9. PubMed ID: 20512074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of ARL4C as a Peritoneal Dissemination-Associated Gene and Its Clinical Significance in Gastric Cancer.
    Hu Q; Masuda T; Sato K; Tobo T; Nambara S; Kidogami S; Hayashi N; Kuroda Y; Ito S; Eguchi H; Saeki H; Oki E; Maehara Y; Mimori K
    Ann Surg Oncol; 2018 Mar; 25(3):745-753. PubMed ID: 29270876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Localization of KRAS downstream target ARL4C to invasive pseudopods accelerates pancreatic cancer cell invasion.
    Harada A; Matsumoto S; Yasumizu Y; Shojima K; Akama T; Eguchi H; Kikuchi A
    Elife; 2021 Sep; 10():. PubMed ID: 34590580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.